[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"localised-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:localised-disease":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100453325","mr-linac-guided-ultra-hypofractionated-rt-for-prostate-cancer-smart-p01-and-smart-p02-100453325",false,"NCT05183074","MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02)","Phase II Prospective Trial of MR-linac Based Stereotactic Ablative Radiotherapy for Patients With Localized (SAMRT-P01) and Oligo-metastatic (SMART-P02) Prostate Cancer","SMART-P01\u002F02","Inclusion Criteria:\n\n* Age≥18 years。\n* Histology confirmed prostate cancer.\n* Risk stratification, localised disease including patients with low-risk(cT1-T2a，PSA \\\u003C10ng\u002FmL，Gleason score≤6) who refuse active surveillance, favorable or unfavorable intermediate-risk and selected high-risk(cT2b-T3a or minimally T3b，PSA 10-40ng\u002FmL，Gleason score 7-8) disease.\n* Oligo-metastatic disease including patients with prostate in-situ and oligometastatic disease (no limit to mets number and organs, with all metastatic foci can be safely treated by radical SBRT dose)\n* ECOG 0-2\n* Postate gland volume ≤100cc\n* IPSS score of \\\u003C18\n* Informed consent: All patients must sign a document of informed consent indicating their understanding of the investigational nature and risks of the study before any protocol related studies are performed\n\nExclusion Criteria:\n\n* Contraindications to MRI.\n* TURP within the past 6 months\n* Ulcerative colitis, Crohn's Disease, ataxia telangiectasia, or systemic lupus erythematosus\n* Previous pelvic irradiation\n* Refuse contraception","MALE","18 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","1. To investigate the tolerability of MR-linac based stereotactic ablative radiotherapy (MRL-SBRT)for patients with localized prostate cancer\n2. To assess the acute and late toxicities, efficacy and quality of life for patients treated by MRL-SBRT\n3. To simulate the dose planning and assess the feasibility of simultaneous-boost for MR-prominent foci\n4. To investigate the relationship between the changes of blood and tissue biomarkers and manifestations on mp-MRI pre-\u002Fpost-MRL-SBRT, to further ascertain the predictive factors of local persisting and\u002For relapse disease",[27,28,29,30,31,32,33],"Prostate Cancer","Radiotherapy Side Effect","Magnetic Resonance-linac","Stereotactic Ablative RT","Adaptive Radiotherapy","Localised Disease","Oligometastatic Disease","RECRUITING","2025-12-04",{"date":37,"type":38},"2025-12-11","ACTUAL",{"date":40,"type":38},"2021-02-01",{"date":42,"type":21},"2027-12-31",{"name":44,"class":45},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER"]